Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A single-institution retrospective analysis of pathologically determined malignant transformation in IDH mutant glioma patients

Autor: Liu, Vicki, Wetzel, Ethan A, Eldred, Blaine SC, Zapanta Rinonos, Serendipity, Prins, Terry J, Khanlou, Negar, Liau, Linda M, Chong, Robert, Nghiemphu, Phioanh L, Cloughesy, Timothy F, Ellingson, Benjamin M, Lai, Albert

Publikováno v: Neuro-oncology advances, vol 5, iss 1

BackgroundLower-grade IDH mutant glioma patients frequently undergo malignant transformation (MT), with apparent worse prognosis. Many studies examine MT in mixed IDH status cohorts and define MT using imaging, not histopathology. Our study examines

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::600d6d8a01d03548d212f0ef0b20bbfc
https://escholarship.org/uc/item/6zk8m7nj

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Epigenetic Induction of Cancer-Testis Antigens and Endogenous Retroviruses at Single-Cell Level Enhances Immune Recognition and Response in Glioma.

Autor: Lai TJ; Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California., Sun L; Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California., Li K; Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California., Prins TJ; Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California., Treger J; Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California., Li T; Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California., Sun MZ; Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California., Nathanson DA; Department of Medical and Molecular Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California., Liau LM; Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.; Department of Medical and Molecular Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California., Lai A; Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.; UCLA Neuro-Oncology Program, University of California, Los Angeles, Los Angeles, California.; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California., Prins RM; Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.; Department of Medical and Molecular Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California.; Parker Institute for Cancer Immunotherapy, San Francisco, California., Everson RG; Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California.

Publikováno v: Cancer research communications [Cancer Res Commun] 2024 Jul 01; Vol. 4 (7), pp. 1834-1849.

A single-institution retrospective analysis of pathologically determined malignant transformation in IDH mutant glioma patients.

Autor: Liu V; Department of Neurology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA., Wetzel EA; Department of Neurology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA., Eldred BSC; Department of Neurology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA., Zapanta Rinonos S; Department of Neurology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA., Prins TJ; Department of Neurology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA., Khanlou N; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA., Liau LM; Department of Neurosurgery, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA., Chong R; Department of Neurology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA., Nghiemphu PL; Department of Neurology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA., Cloughesy TF; Department of Neurology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA., Ellingson BM; Department of Radiological Sciences, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA., Lai A; Department of Neurology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA.

Publikováno v: Neuro-oncology advances [Neurooncol Adv] 2023 Apr 11; Vol. 5 (1), pp. vdad036. Date of Electronic Publication: 2023 Apr 11 (Print Publication: 2023).